Harmony Biosciences Holdings Inc
HRMY
ISIN US4131971040 / Valor 56295735
Harmony Biosciences Holdings Inc
UMushroom community rating:
About company
Harmony Biosciences Holdings Inc, led by President and CEO Jeffrey M. Dayno, focuses on developing next-generation treatments for rare neurological diseases and unmet medical needs. Dr. Dayno's expertise in neuroscience has been instrumental in overseeing the company's business growth, clinical development programs, and pipeline expansion. With a patient-focused drug development model, Harmony Biosciences aims to leverage patient insights to inform its research programs and develop innovative therapies. Dr. Dayno's extensive experience in both patient care and the pharmaceutical industry has positioned the company as a leader in the field, with a strong emphasis on improving the lives of those living with challenging neurological conditions.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
1852 M
Market cap (USD)
108,845
Daily traded volume (Shares)
33.66 / 32.45
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
